| Literature DB >> 30880935 |
Wei Zhang1, Yiwu Zhou1, Bin Bai1, Shikai Yu1, Jing Xiong1, Chen Chi1, Jiadela Teliewubai1, Jue Li2, Jacques Blacher3, Yi Zhang1, Yawei Xu1.
Abstract
BACKGROUND: Left ventricular hypertrophy (LVH) is one of the preclinical manifestations of hypertensive target organ damage (TOD). However, it remains unclear which electrocardiographic criterion perform better in diagnosing LVH.Entities:
Keywords: accuracy; echocardiography; electrocardiography; left ventricular hypertrophy; population study
Mesh:
Year: 2019 PMID: 30880935 PMCID: PMC6417007 DOI: 10.2147/CIA.S180723
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Characteristics of participants by gender
| Characteristics | Overall (n=1,758) | Men (n=784) | Women (n=974) | |
|---|---|---|---|---|
|
| ||||
| Age, years | 71.4±6.1 | 71.4±6.0 | 71.4±6.1 | 0.88 |
| Body height, cm | 160.0±8.3 | 166.4±6.1 | 154.8±5.7 | <0.001 |
| Body weight, kg | 62.5±10.6 | 67.6±10.0 | 58.3±9.1 | <0.001 |
| BMI, kg/m2 | 23.9±3.5 | 23.9±3.2 | 23.9±3.6 | 0.81 |
| BSA, m2 | 1.66±0.17 | 1.76±0.15 | 1.58±0.14 | <0.001 |
| SBP, mmHg | 134.5±17.7 | 134.6±16.7 | 134.4±18.4 | 0.80 |
| DBP, mm Hg | 78.90±9.2 | 79.9±9.3 | 78.1±9.0 | <0.001 |
| Diabetes, n (%) | 336 (19.1) | 146 (18.6) | 190 (19.5) | 0.65 |
| Hypertension, n (%) | 921 (52.4) | 421 (53.8) | 500 (51.3) | 0.31 |
|
| ||||
|
| ||||
| RaVL, mV | 0.42±0.29 | 0.41±0.30 | 0.43±0.28 | 0.14 |
| SV3, mV | 0.72±0.44 | 0.82±0.46 | 0.65±0.42 | <0.001 |
| QRS duration, ms | 91.23±14.61 | 95.90±15.35 | 87.47±12.81 | <0.001 |
| SL index, mV | 2.44±0.80 | 2.61±0.85 | 2.31±0.73 | <0.001 |
| Cornell criterion, mV | 1.15±0.55 | 1.23±0.57 | 1.08±0.53 | <0.001 |
| CP criterion, mV/ms | 134.7±60.3 | 118.8±64.7 | 147.5±53.1 | <0.001 |
|
| ||||
|
| ||||
| IVS, mm | 9.47±1.87 | 9.61±1.94 | 9.38±1.81 | 0.011 |
| PWT, mm | 9.10±1.56 | 9.27±1.57 | 8.96±1.54 | <0.0001 |
| LVID, mm | 46.71±6.80 | 47.90±7.05 | 45.75±6.43 | <0.0001 |
| LVM, g | 151.1±53.1 | 161.0±57.1 | 143.1±48.1 | <0.0001 |
| LVM/BSA, g/m2 | 90.5±28.9 | 90.8±29.7 | 90.3±28.3 | 0.74 |
| LVM/height2.7, g/m2.7 | 42.7±15.1 | 40.8±14.3 | 44.2±15.5 | <0.0001 |
Notes: Data means ± SD or numbers with percentages in parenthesis. Student’s t-test and chi-squared analysis were conducted for the comparison of continuous and dichotomized variables between men and women.
Abbreviations: BMI, body mass index; BSA, body surface area; CP, Cornell Product; ECG, electrocardiography; ECHO, echocardiography; height2.7, LVM indexed for 2.7 power of body height; IVS, interventricular septum; LVID, left ventricular internal diameter; LVM, left ventricular mass; LVMI/BSA, LVM indexed for BSA; LVMI/PWT, LVM indexed for posterior wall thickness; PWT, posterior wall thickness; RaVL, R wave of lead aVL; SL, Sokolow-Lyon; SV3, S wave of the leads V3.
Characteristics of participants by hypertensive status
| Characteristics | Overall (n=1,757) | Hypertension (n=921) | No hypertension (n=836) | |
|---|---|---|---|---|
|
| ||||
| Age, years | 71.4±6.1 | 72.0±6.2 | 70.8±5.8 | <0.001 |
|
| ||||
|
| ||||
| RaVL, mV | 0.42±0.29 | 0.46±0.30 | 0.38±0.26 | <0.001 |
| SV3, mV | 0.72±0.44 | 0.77±0.47 | 0.68±0.42 | <0.001 |
| QRS duration, ms | 91.22±14.61 | 91.88±15.26 | 90.48±13.82 | 0.044 |
| SL index, mV | 2.44±0.80 | 2.54±0.84 | 2.33±0.74 | <0.001 |
| Cornell criterion, mV | 1.15±0.55 | 1.23±0.58 | 1.06±0.51 | <0.001 |
| CP criterion, mV/ms | 134.7±60.3 | 143.0±65.2 | 125.5±52.8 | <0.001 |
|
| ||||
|
| ||||
| IVS, mm | 9.49±1.87 | 9.79±1.96 | 9.15±1.71 | <0.001 |
| PWT, mm | 9.10±1.56 | 9.30±1.62 | 8.88±1.46 | <0.001 |
| LVID, mm | 46.70±6.79 | 47.73±6.88 | 45.57±6.52 | <0.001 |
| LVM, g | 151.0±53.0 | 161.8±55.6 | 139.1±47.2 | <0.001 |
| LVM/BSA, g/m2 | 90.5±28.9 | 95.7±29.8 | 84.7±26.7 | <0.001 |
| LVM/height2.7, g/m2.7 | 42.7±15.1 | 45.7±15.3 | 39.3±14.1 | <0.001 |
Abbreviations: BSA, body surface area; CP, Cornell Product; ECG, electrocardiography; ECHO, echocardiography; IVS, interventricular septum; LVID, left ventricular internal diameter; height2.7, LVM indexed for 2.7 power of body height; LVM, left ventricular mass; PWT, posterior wall thickness; RaVL, R wave of lead aVL; SL, Sokolow-Lyon; SV3, S wave of the leads V3.
Correlation coefficient (R) between the electrocardiographic and echocardiographic parameters for the detection of LVHin total participants, in both males and females
| Index | SL (SV1 + RV5)
| Cornell (SV3 + RaVL)
| CP (SV3 + RaVL) × QRS duration
| ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
|
| |||||||
| Total | 0.15 | <0.001 | 0.16 | <0.001 | 0.18 | <0.001 | |
| Male | 0.23 | <0.001 | 0.17 | <0.001 | 0.21 | <0.001 | |
| Female | 0.09 | <0.01 | 0.15 | <0.001 | 0.16 | <0.001 | |
|
| |||||||
|
| |||||||
| Total | 0.09 | <0.001 | 0.15 | <0.001 | 0.21 | <0.001 | |
| Male | 0.20 | <0.001 | 0.17 | <0.001 | 0.21 | <0.001 | |
| Female | 0.05 | 0.091 | 0.17 | <0.001 | 0.17 | <0.001 | |
Note: Pearson’s correlation analysis was applied between the electrocardiographic and echocardiographic parameters for the detection of LVH in total participants, in both males and females.
Abbreviations: BSA, body surface area; CP, Cornell Product; LVM, left ventricular mass; RaVL, R wave of lead aVL; RV5, R wave of lead V5; SL, Sokolow-Lyon; SV1, S wave of the leads V1; SV3, S wave of the leads V3.
Chi-squared test between LVH diagnosed by ECG and by ECHO
| Index | LVH1: LVM/BSA M ≥125 g/m2, F ≥110 g/m2
| LVH2: LVM/BSA M ≥115 g/m2, F ≥95 g/m2
| LVH3: LVM/height2.7 M ≥51 g/m2.7, F ≥47 g/m2.7
| |||
|---|---|---|---|---|---|---|
|
| ||||||
|
| ||||||
| SL-China (M ≥4.0 mV, F ≥3.5 mV) | 24.15 | <0.001 | 16.00 | <0.001 | 15.99 | <0.001 |
| SL (M/F ≥3.5 mV) | 14.34 | <0.001 | 7.52 | <0.01 | 9.67 | <0.01 |
| Cornell (M ≥2.8 mV, F ≥2.0 mV) | 5.92 | 0.02 | 4.30 | 0.04 | 5.51 | 0.02 |
| CP (M/F ≥244 mV/ms) | 2.71 | 0.10 | 5.10 | 0.02 | 9.23 | <0.01 |
Abbreviations: BSA, body surface area; CP, Cornell Product; ECG, electrocardiography; ECHO, echocardiography; F, female; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVH1, LVH diagnosed by LVM indexed for BSA (LVMI ≥125 g/m2 in males and ≥110 g/m2 in females); LVH2, LVH diagnosed by LVM indexed for BSA (LVMI ≥115 g/m2 in males and ≥95 g/m2 in females); LVH3, LVH diagnosed by LVM indexed for body height2.7 (LVMI2 ≥51 g/m2.7 in males and ≥47 g/m2.7 in females); M, male; SL, Sokolow-Lyon.
Figure 1ROC curve with three electrocardiographic criteria for detecting LVH1, LVH2, and LVH3, the ROC curve for defining LVH1 using LVM indexed for BSA (LVMI) ≥125 g/m2 in males and ≥110 g/m2 in females; the ROC curve for defining LVH2 using LVM indexed for BSA (LVMI) ≥115 g/m2 in males and ≥95 g/m2 in females; the ROC curve for defining LVH3 using LVM indexed for BSA (LVMI2) ≥51 g/m2.7 in males and ≥47 g/m2.7 in females. N indicates P>0.05 and **indicates P<0.01.
Abbreviations: AUC, area under curve; BSA, body surface area; CP, Cornell Product; LVH, left ventricular hypertrophy; LVM, left ventricular mass; ROC, receiver operating characteristic; SL, Sokolow-Lyon.